



LKT Laboratories, Inc.

GSK-1120212

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)

Web: [lktlabs.com](http://lktlabs.com)

## Product Information

Product ID G7440

CAS No. 871700-17-3

### Chemical Name

Synonym Trametinib, JTP-74057

Formula  $C_{26}H_{23}FIN_5O_4$

Formula Wt. 615.39

### Melting Point


Purity  $\geq 98\%$

Solubility DMSO (10 mg/ml)  
Water Insoluble  
Ethanol Insoluble

Store Temp  $-20^{\circ}C$

Ship Temp Ambient

**Description** GSK-1120212 inhibits MEK1/2 and is currently in clinical trials as a potential treatment for melanoma. GSK-1120212 exhibits anticancer chemotherapeutic activity, upregulating p27 expression and inhibiting growth in colorectal cancer cells and suppressing tumor growth in colorectal cancer xenografts.



**Bulk quantities available upon request**

Product ID	Size
------------	------

G7440	5 mg
-------	------

G7440	25 mg
-------	-------

G7440	100 mg
-------	--------

**References** Hartsough EJ, Basile K, Aplin AE. Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-expressing Melanoma. Mol Cancer Res. 2014 Feb 11. [Epub ahead of print]. PMID: 24520098.

Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 1;31(4):482-9. PMID: 23248257.

Yamaguchi T, Kakefuda R, Tajima N, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011 Jul;39(1):23-31. PMID: 21523318.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.